Recurrent Melanoma Recruiting Phase 2 Trials for DB08912 (Dabrafenib)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02196181Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by SurgeryTreatment
NCT02465060NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple MyelomaTreatment